Featured Research Search Results
Treating Advanced Cancers with DNA-Repair Mutations Using MOMA-313 Alone or In Combination with the PARP Inhibitor Olaparib
Clinicaltrials.gov identifier:
NCT06545942
Treatment
Treatment study for people with advanced or metastatic cancers
Using a Blood Test to Detect Early Cancer Recurrence After Treatment (ORACLE)
Clinicaltrials.gov identifier:
NCT05059444
Treatment
Post-treatment study to monitor for recurrence
Treating Advanced or Metastatic Breast Cancer with a Type of Immunotherapy Called CAR-T
Clinicaltrials.gov identifier:
NCT06878248
Treatment
Phase 1 treatment study for people with advanced solid tumors
Comparing a New Drug, Palazestrant, to Standard Treatment for Advanced Breast Cancer
Clinicaltrials.gov identifier:
NCT06016738
Treatment
Phase 3 study for ER-positive, HER2-negative advanced or metastatic breast cancer
Comparing Hormone Therapy With and Without Chemotherapy for Premenopausal Breast Cancer (OFSET)
Clinicaltrials.gov identifier:
NCT05879926
Treatment
Phase 3 study for premenopausal women with early-stage ER positive, HER2-negative breast cancer
Treating Advanced Breast or Other Solid Cancers Using a Combination of a New Targeted Therapy, ZEN003694, With The Targeted Therapy Abemaciclib (Verzenio)
Clinicaltrials.gov identifier:
NCT05372640
Treatment
Phase 1 treatment study for advanced breast cancer and other solid tumors
Study of a New Targeted Therapy Given Alone or in Combination with an Immunotherapy for Metastatic, Triple-Negative Breast Cancer
Clinicaltrials.gov identifier:
NCT06841354
Treatment
Phase 3 treatment study for people with metastatic, triple-negative breast cancer
Study of a New Investigational Inhibitor to Treat People with Advanced Solid Tumors
Clinicaltrials.gov identifier:
NCT05932862
Treatment
Treatment study for people with advanced solid tumors
Using a PARP Inhibitor and Oral Chemotherapy to Treat Advanced Solid Tumors with a Mutation in BRCA1, BRCA2, PALB2, ATM or CHEK2
Clinicaltrials.gov identifier:
NCT06177171
Treatment
Phase 1 treatment study for metastatic solid tumors
A New Targeted Therapy CX‑5461 to Treat Advanced Breast, Ovarian, Pancreatic or Prostate Cancer with Inherited or Tumor Mutations
Clinicaltrials.gov identifier:
NCT04890613
Treatment
Phase 1 treatment study for advanced or metastatic breast, ovarian, pancreatic or prostate cancer
Studying a New PARP Inhibitor and Hormonal Therapy to Treat HER2-negative, HR-positive Metastatic Breast Cancer with a BRCA1, BRCA2, or PALB2 Mutation (EvoPAR BR01)
Clinicaltrials.gov identifier:
NCT06380751
Treatment
Phase 3 treatment study for HER2-negative, HR-positive metastatic breast cancer with a BRCA1, BRCA2 or PALB2 mutation
Treating Advanced or Metastatic Cancers with a New PARP Inhibitor (GS-0201) Alone or Combined with Other Drugs
Clinicaltrials.gov identifier:
NCT06167317
Treatment
Treatment study for people with advanced or metastatic solid tumors
Treating HER2-negative, Metastatic Breast Cancer with a BRCA or PALB2 Mutation Using a New Drug Combined with Olaparib
Clinicaltrials.gov identifier:
NCT06488378
Treatment
Treatment study for HER2-negative, metastatic breast cancer with a BRCA1/2 or PALB2 mutation
Looking at Tumor DNA Before Chemotherapy to Predict Cancer Recurrence in People with High-Risk, Early-Stage Breast Cancer
Clinicaltrials.gov identifier:
NCT06401421
Treatment
Biomarker study for people with early-stage breast cancer
Testing a Shorter Course of Chemo- and Immunotherapy for People With Early-Stage Triple-Negative Breast Cancer
Clinicaltrials.gov identifier:
NCT05929768
Treatment
Treatment study for early-stage triple-negative breast cancer
Olaparib with Cediranib or Ceralasertib for People with Advanced or Metastatic Breast Cancer and with a BRCA1 or BRCA2 Mutation
Clinicaltrials.gov identifier:
NCT04090567
Treatment
Treatment study for people with advanced breast cancer who have a BRCA1 or BRCA2 genetic mutation and who were previously treated with a PARP inhibitor
New Treatment in People with Triple Negative Breast Cancer or Advanced Solid Tumors
Clinicaltrials.gov identifier:
NCT06022029
Treatment
Treatment study for people with triple negative breast cancer, advanced solid tumors or lymphomas
Study of the PARP inhibitor AZD9574 Alone and Combined with Other Cancer Medicines to Treat People with Advanced Solid Cancers (CERTIS1 Study)
Clinicaltrials.gov identifier:
NCT05417594
Treatment
Treatment study for people with advanced breast, ovarian, pancreatic or prostate cancer or gliomas
Sponsored By
